2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 602

Repeat Biopsy In Lupus Nephritis: A Single-Center Experience
Abstract Number: 1453

Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Abstract Number: 274

Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Abstract Number: 1898

Repression Of Wolf-Hischhorn Syndrome Candidate-1 (WHSC1) Contributes To The Osteoarthritis-Inducing Cartilage Loss Of Functions
Abstract Number: 989

Reproductive Counseling Program For Lupus Patients At The Systemic Lupus Erythematosus-Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery
Abstract Number: 2266

Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study
Abstract Number: 6

Researchers’ Own Experience In Managing Obstetric Complications In Pregnant Women With Antiphospholipid Syndrome
Abstract Number: 2745

Reshaping Inflammatory Macrophage Development and Functions by a Monosaccharide Analogue In Rheumatoid Arthritis
Abstract Number: 1214

Resistant Or Recurrent Acute Pericarditis: A New Therapeutic Opportunity?
Abstract Number: 521

Respiratory Compromise In Patients With Primary Sjögren Syndrome
Abstract Number: 2405

Respiratory Diseases As Risk Factors For Rheumatoid Arthritis
Abstract Number: 878

Responders To Tocilizumab Identified By Serological Measurement Of Connective Tissue Type I Collagen In Patients With Rheumatoid Arthritis
Abstract Number: 2247

Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Abstract Number: 484

Response To Biologic Disease-Modifying Anti-Rheumatic Drugs After Discontinuation Of Anti-Tumor Necrosis Factor Alpha Agents In Rheumatoid Arthritis Patients
Abstract Number: 355

Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].